primary antibodies against cd73  (Proteintech)

Journal: Scientific reports

Article Title: Increased primary breast tumor expression of CD73 is associated with development of bone metastases and is a potential biomarker for adjuvant bisphosphonate use.

doi: 10.1038/s41598-025-92841-9

Figure Lengend Snippet: Fig. 1. Representative images of immunostaining for CD73 in TMA cores from patients in the AZURE study. (A) Images of protein expression obtained using the anti-CD73 antibody and visualized at a magnification of 20x. Score 0–3 categories were determined by the intensity of staining in the cytoplasmic compartment of tumor cells only. Scale bar = 200 μm. (B) 40x magnification view of from the boxed regions depicted in panel A. Scale bar of core view = 100 μm. Scale bar of 40x = 50 μm.

Article Snippet: After cooling and washing, slides were blocked with normal goat serum for 1 h at room temperature, after which primary antibodies against CD73 (CST, 13160, 1:1000) were applied (overnight, 4 °C).

Techniques: Immunostaining, Expressing, Staining

Journal: Scientific reports

Article Title: Increased primary breast tumor expression of CD73 is associated with development of bone metastases and is a potential biomarker for adjuvant bisphosphonate use.

doi: 10.1038/s41598-025-92841-9

Figure Lengend Snippet: Fig. 2. Prognostic value of CD73 levels in clinical events. Kaplan-Meier association of CD73 expression level in Overall Survival (OS) in (A) control and (B) zoledronic acid arms. Relationship between level of expression of CD73 in Disease-Free-Survival (DFS) in (C) control and (D) zoledronic acid arms. P-value is obtained from the log-rank test for testing quality of survival Q15 functions.

Article Snippet: After cooling and washing, slides were blocked with normal goat serum for 1 h at room temperature, after which primary antibodies against CD73 (CST, 13160, 1:1000) were applied (overnight, 4 °C).

Techniques: Expressing, Control

Journal: Scientific reports

Article Title: Increased primary breast tumor expression of CD73 is associated with development of bone metastases and is a potential biomarker for adjuvant bisphosphonate use.

doi: 10.1038/s41598-025-92841-9

Figure Lengend Snippet: Fig. 3. Kaplan-Meier association of CD73 levels with clinical metastatic events. Relationship between CD73 expression to time to first bone recurrence, – where cancer spread to bone is the first recorded event in (A) control and (B) zoledronic acid arm. Relationship between level of CD73 expression to spread to bone at any time (for which patients may have had spread to non-bone sites first) in (C) control and (D) zoledronic acid arm. Relationship between CD73 expression to time to spread to non-bone sites in (E) control and (F) zoledronic acid arm. P-value is obtained from the log-rank test for testing quality of survival Q15 function.

Article Snippet: After cooling and washing, slides were blocked with normal goat serum for 1 h at room temperature, after which primary antibodies against CD73 (CST, 13160, 1:1000) were applied (overnight, 4 °C).

Techniques: Expressing, Control

Journal: International Journal of Molecular Sciences

Article Title: Prevention of Transition from Acute Kidney Injury to Chronic Kidney Disease Using Clinical-Grade Perinatal Stem Cells in Non-Clinical Study

doi: 10.3390/ijms25179647

Figure Lengend Snippet: ( a ) Flow cytometry data of MSCs derived from the placenta of three donors indicate uniform MSC purity across samples from different donors. ( b ) More than 95% of the cells from each donor consistently expressed CD73, CD90, and CD105, confirming their mesenchymal identity. Endothelial (CD31), hematopoietic (CD45), and antigen-presenting (HLA-DR) markers were present in less than 1% of the cells, demonstrating minimal non-mesenchymal lineage presence and a repeatable manufacturing process.

Article Snippet: The hpMSCs were incubated with primary antibodies against CD31-APC, CD45, CD73, CD90, and HLA-DR (BD FACSDiva) to assess the formation of osteoblasts, adipocytes, and chondrocytes.

Techniques: Flow Cytometry, Derivative Assay

Journal: PLoS ONE

Article Title: Long Term Expansion of Bone Marrow-Derived hMSCs on Novel Synthetic Microcarriers in Xeno-Free, Defined Conditions

doi: 10.1371/journal.pone.0092120

Figure Lengend Snippet: (A) Quantitative marker analysis showing percent of cells expressing CD73, CD105, CD14 and CD45 after long term expansion Synthemax II microcarriers in Mesencult XF and hMSC stemgro media. Flow cytometry histograms for each phenotypic marker are shown for cells maintained on Synthemax II microcarriers in Mesencult XF medium (B) and hMSC stemgro medium (C).

Article Snippet: Cells were incubated in blocking buffer for 15 min at 4°C, followed by 30 minute incubation at 4°C with primary antibodies against CD14, CD45, CD73, CD105 (Millipore Chemicon) or corresponding isotype controls (Invitrogen/Molecular Probes) in blocking buffer.

Techniques: Marker, Expressing, Flow Cytometry